Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Shinya Omoto"'
Autor:
Satoshi Iwata, Andrew J. Pollard, Yukio Tada, Shinya Omoto, Risa Y. Shibata, Kenji Igarashi, Takahiro Hasegawa, Mari Ariyasu, Takuhiro Sonoyama
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract We assessed S-268019-b, a recombinant spike protein vaccine with a squalene-based adjuvant, for superiority in its immunogenicity over ChAdOx1 nCoV-19 vaccine among adults in Japan. In this multicenter, randomized, observer-blinded, phase 3
Externí odkaz:
https://doaj.org/article/817d308450f6499888e53a12afff8455
Autor:
Tomoyuki Homma, Noriyo Nagata, Masayuki Hashimoto, Naoko Iwata-Yoshikawa, Naomi M. Seki, Nozomi Shiwa-Sudo, Akira Ainai, Keiji Dohi, Eiji Nikaido, Akiko Mukai, Yuuta Ukai, Takayuki Nakagawa, Yusuke Shimo, Hiroki Maeda, Seiki Shirai, Miwa Aoki, Takuhiro Sonoyama, Mamoru Sato, Masataka Fumoto, Morio Nagira, Fumihisa Nakata, Takao Hashiguchi, Tadaki Suzuki, Shinya Omoto, Hideki Hasegawa
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-3 (2024)
Externí odkaz:
https://doaj.org/article/2c929b0e73d8402c9d1d873ce59791d3
Autor:
Takuhiro Sonoyama, Akari Kamitani, Risa Y. Shibata, Naomi M. Seki, Shinya Omoto, Kenji Igarashi, Mari Ariyasu
Publikováno v:
Vaccine: X, Vol 15, Iss , Pp 100390- (2023)
Despite the initial success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in prevention of symptomatic and severe diseases, booster vaccination has become increasingly important with the advent of variants with immune-escap
Externí odkaz:
https://doaj.org/article/528b0e79253d4baaadff6143a85a0635
Autor:
Tomoyuki Homma, Noriyo Nagata, Masayuki Hashimoto, Naoko Iwata-Yoshikawa, Naomi M. Seki, Nozomi Shiwa-Sudo, Akira Ainai, Keiji Dohi, Eiji Nikaido, Akiko Mukai, Yuuta Ukai, Takayuki Nakagawa, Yusuke Shimo, Hiroki Maeda, Seiki Shirai, Miwa Aoki, Takuhiro Sonoyama, Mamoru Sato, Masataka Fumoto, Morio Nagira, Fumihisa Nakata, Takao Hashiguchi, Tadaki Suzuki, Shinya Omoto, Hideki Hasegawa
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-17 (2022)
Abstract Vaccines that efficiently target severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent for coronavirus disease (COVID-19), are the best means for controlling viral spread. This study evaluated the efficacy of th
Externí odkaz:
https://doaj.org/article/99ad8a52d26d4caea59d78b78fe4a764
Autor:
Harry L. Stannard, Edin J. Mifsud, Steffen Wildum, Sook Kwan Brown, Paulina Koszalka, Takao Shishido, Satoshi Kojima, Shinya Omoto, Keiko Baba, Klaus Kuhlbusch, Aeron C. Hurt, Ian G. Barr
Publikováno v:
Communications Biology, Vol 5, Iss 1, Pp 1-12 (2022)
A clinical influenza isolate with dual antiviral resistant mutations displays a moderate loss of viral fitness in ferrets compared to wild-type virus, suggesting widespread community transmission of this dual mutant is unlikely.
Externí odkaz:
https://doaj.org/article/450f13fea2434b3a881cfa9fa16c3fa5
Autor:
Yuya Yoshioka, Kouji Kobiyama, Tomoya Hayashi, Motoyasu Onishi, Yosuke Yanagida, Takayuki Nakagawa, Masayuki Hashimoto, Anri Nishinaka, Jun Hirose, Yoshiji Asaoka, Minako Tajiri, Atsushi Hayata, Satoru Ishida, Shinya Omoto, Morio Nagira, Ken J. Ishii
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundAdjuvants are chemical or biological materials that enhance the efficacy of vaccines. A-910823 is a squalene-based emulsion adjuvant used for S-268019-b, a novel vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) t
Externí odkaz:
https://doaj.org/article/660750c5f8eb4c1bbea1804e0ac9e01b
Autor:
Leo Y Lee, Jie Zhou, Paulina Koszalka, Rebecca Frise, Rubaiyea Farrukee, Keiko Baba, Shahjahan Miah, Takao Shishido, Monica Galiano, Takashi Hashimoto, Shinya Omoto, Takeki Uehara, Edin J Mifsud, Neil Collinson, Klaus Kuhlbusch, Barry Clinch, Steffen Wildum, Wendy S Barclay, Aeron C Hurt
Publikováno v:
PLoS Pathogens, Vol 17, Iss 5, p e1009527 (2021)
Baloxavir is approved in several countries for the treatment of uncomplicated influenza in otherwise-healthy and high-risk patients. Treatment-emergent viruses with reduced susceptibility to baloxavir have been detected in clinical trials, but the li
Externí odkaz:
https://doaj.org/article/6a080755b2e74791b2fa666dd6d94232
Autor:
Masayuki Hashimoto, Shinpei Aoe, Yusuke Kawazu, Naomi M. Seki, Kumi Hashimoto, Ken Yoshihara, Tomoyuki Homma, Takuhiro Sonoyama, Shinya Omoto
Publikováno v:
Vaccine. 40:7520-7525
SARS-CoV-2 Omicron subvariants such as BA.2.12.1, BA.4 and BA.5 have been spreading rapidly and become dominant worldwide. Here we report the homologous or heterologous booster effects of S-268019-b, a recombinant spike protein vaccine with the squal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47129ce209172920d047944e5f8e6ebc
https://doi.org/10.1016/j.vaccine.2022.10.092
https://doi.org/10.1016/j.vaccine.2022.10.092
Autor:
Masayuki Hashimoto, Noriyo Nagata, Tomoyuki Homma, Hiroki Maeda, Keiji Dohi, Naomi M. Seki, Ken Yoshihara, Naoko Iwata-Yoshikawa, Nozomi Shiwa-Sudo, Yusuke Sakai, Masayuki Shirakura, Noriko Kishida, Tomoko Arita, Yasushi Suzuki, Shinji Watanabe, Hideki Asanuma, Takuhiro Sonoyama, Tadaki Suzuki, Shinya Omoto, Hideki Hasegawa
Publikováno v:
Vaccine. 40:4231-4241
The vaccine S-268019-b is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S)-protein vaccine consisting of full-length recombinant SARS-CoV-2 S-protein (S-910823) as antigen, mixed with the squalene-based adjuvant A-910823. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a82705baf1dda87ede110571ed5957c
https://doi.org/10.1016/j.vaccine.2022.05.081
https://doi.org/10.1016/j.vaccine.2022.05.081
Autor:
Masaharu Shinkai, Takuhiro Sonoyama, Akari Kamitani, Risa Yokokawa Shibata, Naomi M. Seki, Shinya Omoto, Masahiro Shinoda, Takashi Sato, Naoki Ishii, Kenji Igarashi, Mari Ariyasu
Publikováno v:
Vaccine. 40:4328-4333
In this randomized, observer-blinded, phase 2/3 study, S-268019-b (n = 101), a recombinant spike protein vaccine, was analyzed for noninferiority versus BNT162b2 (n = 103), when given as a booster ≥6 months after 2-dose BNT162b2 regimen in Japanese
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afcf648eeaa02bb0d266223b671e6b82
https://doi.org/10.1016/j.vaccine.2022.06.032
https://doi.org/10.1016/j.vaccine.2022.06.032